Clinical Trials Browser

Active not recruiting × INDUSTRY × Smoldering Multiple Myeloma × Clear all

NCT03301220 2026-03-18

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Phase 3 Active not recruiting

390 enrolled 12 charts 1 FDA

Smoldering Multiple Myeloma

NCT05955508 2026-02-23

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

Phase 2 Active not recruiting

Smoldering Multiple Myeloma, Multiple Myeloma